CLVLY
Clinuvel Pharmaceuticals Ltd
CEO
Philippe Wolgen
Industry
Research and Development in Biotechnology
Loading...
Open
7.36
Mkt cap
376M
Volume
650
High
7.50
P/E Ratio
15.31
52-wk high
11.40
Low
7.36
Div yield
0.00
52-wk low
6.80
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.